Is There Intravascular Hemolysis in Patients With Pulmonary Hypertension?

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2007 by Rabin Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Rabin Medical Center
ClinicalTrials.gov Identifier:
NCT00502398
First received: July 15, 2007
Last updated: October 14, 2007
Last verified: October 2007
  Purpose

Patients with hemolytic disorders (e.g. sickle cell anemia or thalassemia) are known to develop pulmonary hypertension. Hemolysis is where red blood cells are destroyed and their contents released into the circulation. It is thought that these red-cell contents cause constriction and thrombosis of the blood vessels in the lungs. Conversely, it is possible that patients with pulmonary hypertension have hemolysis.

In this study we will be drawing blood from a range of patients and normal controls for a panel of blood tests related to hemolysis.


Condition Intervention
Pulmonary Artery Hypertension
Procedure: Blood test

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Rabin Medical Center:

Study Start Date: September 2007
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

One of the following four conditions :

  • Pulmonary artery hypertension
  • Obstructive sleep apnea with pulmonary hypertension
  • Lung transplant candidates without pulmonary hypertension
  • Normal Controls

Exclusion Criteria:

  • Known hemolytic disorder
  • Recent blood loss (<3 months)
  • Recent blood transfusion (<3 months)
  • Liver disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00502398

Contacts
Contact: Ben Fox, MRCP +972 3 937 7221 foxb@clalit.org.il

Locations
Israel
Pulmonary Institute, Rabin Medical Center (Beilinson campus) Recruiting
Petach Tikva, Israel, 49100
Contact: Ben Fox, MRCP       foxb@clalit.org.il   
Sponsors and Collaborators
Rabin Medical Center
Investigators
Principal Investigator: Mordechai Kramer, MD Rabin Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00502398     History of Changes
Other Study ID Numbers: RMC074490CTIL
Study First Received: July 15, 2007
Last Updated: October 14, 2007
Health Authority: Israel: Clalit Health Services

Additional relevant MeSH terms:
Hypertension
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 21, 2014